This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
The product information for the Comirnaty original COVID-19 vaccine (formerly COVID-19 Vaccine Pfizer/BioNTech) can be found on a separate page.
Comirnaty Original/Omicron BA.4/5 are vaccines used for preventing COVID-19 caused by SARS‑CoV-2.
Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose is for use in adults and adolescents from 12 years of age and older.
Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose is for use in children aged 5 to 11 years.
Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose is for use in children aged 6 months to 4 years
They are only for individuals who have previously received at least a primary vaccination course against COVID-19.
The vaccines cause the immune system (the body’s natural defences) to produce antibodies and blood cells that work against the virus, so giving protection against COVID-19.
As these vaccines do not contain the virus to produce immunity, they cannot give you COVID-19.
Updates to this page
Last updated:
8 August 2024
Show all updates
Removed 'Summary of Product Characteristics - Pfizer/BioNTech bivalent vaccine - Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose for age 12+' and 'Patient Information Leaflet - Pfizer/BioNTech bivalent vaccine - Comirnaty Original /Omicron BA.4-5 (15/15 micrograms)/dose for age 12+' Following the recent withdrawal of the licences for this Comirnaty (COVID-19 vaccines) vaccine.
The product information (SmPC and PIL) of each Comirnaty product has been updated following recent approval on PI updates (Sections 1, 2, and 4.8, and labelling) and shelf-life extension.
Update to section 4.8 of the SmPC to update the safety information available in 12-15 year olds.
Updated 'Summary of Product Characteristics - Pfizer/BioNTech bivalent vaccine - BA.4-5 (1.5/1.5 micrograms)/dose for age 6 months to 4 years' to reflect an update to the product shelf-life (Section 6.3 of the SmPC), from 18 months to 2 years.
Updated the PIL and SmPC for the Comirnaty bivalent vaccine Original/Omicron BA.4-5 (1.5/1.5 microgram)/dose for use in infants and children aged 6m to 4 years following approval of the Comirnaty Omicron XBB.1.5 vaccines and to update information on myocarditis.
Summary of Product Characteristics and Patient Information Leaflet added for 'Comirnaty Original/Omicron BA.4-5 for use in infants and children aged 6 months to 4 years' - Date of first authorisation - 31 Aug 23.
Summary of Product Characteristics (SmPC) and Patient Information Leaflets (PIL) updated to reflect: A variation to reflect new posology for primary immunisation and a variation to extend the shelf-life. The updates affect all Comirnaty Original/Omicron BA.4-5 products. Updates applicable from 24 August 2023.
Updated safety and immunogenicity information has been added to the product information based on six months post-booster dose follow-up data in recipients aged 16 years and older.
Updated SPCs and PILs for all Comirnaty products, to include: the uncommon side effect ‘dizziness’
& longer-term clinical trial follow-up data in 5-11 year olds.
Product information has been added for a new, age-appropriate presentation of the bivalent version of the vaccine Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose, which is for use in children aged 5 to 11 years. Minor, consequential updates were made to the product information for the Comirnaty Original/Omicron BA.1 (15/15 micrograms)/dose for use in adults and adolescents from 12 years of age and older, and Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose, also for use in adults and adolescents from 12 years of age and older.